Health and Fitness Health and Fitness
Tue, May 1, 2012
Mon, April 30, 2012
[ Mon, Apr 30th 2012 ] - Market Wire
Hologic to Acquire Gen-Probe
Sun, April 29, 2012
Sat, April 28, 2012
Fri, April 27, 2012
Thu, April 26, 2012
Wed, April 25, 2012
Tue, April 24, 2012
Mon, April 23, 2012
Sun, April 22, 2012
Sat, April 21, 2012
Fri, April 20, 2012
Thu, April 19, 2012
Wed, April 18, 2012
[ Wed, Apr 18th 2012 ] - Market Wire
00 a.m. ET

30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2012


//health-fitness.news-articles.net/content/2012/ .. results-for-the-quarter-ended-march-31-2012.html
Published in Health and Fitness on Tuesday, April 24th 2012 at 14:00 GMT by Market Wire   Print publication without navigation


LEXINGTON, Mass.--([ ])--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2012 after the U.S. financial markets close on Tuesday, May 1, 2012. The announcement will be followed by a conference call and webcast with slides at 4:30 p.m. ET during which management will discuss the companyas financial results, commercial progress and development programs.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 5:30 p.m. ET on May 1, 2012 through midnight May 8, 2012. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 73223897.

The call will be webcast with slides and accessible through the Investors section of the companyas website at [ www.amagpharma.com ]. The webcast replay will be available from approximately 5:30p.m. ET on May 1, 2012 through midnight June 1, 2012.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures and sells Feraheme (ferumoxytol) Injection for intravenous use. For additional company or product information, please visit [ www.amagpharma.com ] or [ http://feraheme.com ].

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.


Publication Contributing Sources